World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
56
Citations
12081
World Ranking
3712
National Ranking
325

Frank A. Post publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Frank A. Post sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 260 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Frank A. Post D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Frank A. Post sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 56 D-Index — 26th percentile

26% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Frank A. Post is a researcher affiliated with King's College London in the United Kingdom. Their work primarily focuses on the field of Medicine, with substantial contributions in Infectious Diseases, Emergency Medicine, Epidemiology, Nephrology, and Virology.

Their main research topics encompass various aspects of HIV and related health issues, including:

  • HIV-related health complications and treatments
  • HIV/AIDS research and interventions
  • HIV/AIDS drug development and treatment
  • Pneumocystis jirovecii pneumonia detection and treatment
  • HIV research and treatment
  • Renal diseases and glomerulopathies
  • Pharmacological effects and toxicity studies

Frank A. Post has contributed to a significant number of publications, many of which appeared in notable journals such as HIV Medicine, AIDS, International Journal of STD & AIDS, Kidney International Reports, and Clinical Infectious Diseases.

Their frequent co-authors include:

  • Caroline Sabin
  • Lucy Campbell
  • Julie Fox
  • Jane Anderson
  • Lisa Hamzah

Among recent papers featuring their involvement are:

  • "Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial," published in 2020 in The Lancet
  • "Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial," published in 2020 in The Lancet
  • "Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials," published in 2021 in Clinical Infectious Diseases
  • "Hospitalized Patients With COVID-19 and Human Immunodeficiency Virus: A Case Series," published in 2020 in Clinical Infectious Diseases
  • "Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial," published in 2021 in The Lancet HIV

Best Publications

  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

    Paul E Sax;David Wohl;Michael T Yin;Frank Post

  • Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

    Paul E. Sax;Kristine M. Erlandson;Jordan E. Lake;Grace A. McComsey

  • Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy

    Margaret T. May;Mark Gompels;Valerie Delpech;Kholoud Porter

  • Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study

    Margaret T May;Mark Gompels;Valerie Delpech;Kholoud Porter

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012

    Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).

    Amanda Mocroft;Jens D Lundgren;Jens D Lundgren;Miriam Lewis Sabin;Antonella d'Arminio Monforte

  • Mycobacterium tuberculosis Growth at the Cavity Surface: a Microenvironment with Failed Immunity

    Gilla Kaplan;Frank A. Post;Andre L. Moreira;Helen Wainwright

  • Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

    Kenneth H Mayer;Kenneth H Mayer;Jean-Michel Molina;Melanie A Thompson;Peter L Anderson

  • Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients

    Juliano Timm;Frank A. Post;Linda-Gail Bekker;Gabriele B. Walther

  • Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study.

    Clark D Russell;Cameron J Fairfield;Thomas M Drake;Lance Turtle

  • Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

    Frank A Post;Graeme J Moyle;Hans Jürgen Stellbrink;Pere Domingo

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

    Ian Williams;Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: A randomized phase 2 study

    Paul E. Sax;Andrew Zolopa;Indira Brar;Richard Elion

  • Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    Charles R. Swanepoel;Mohamed G. Atta;Vivette D. D’Agati;Michelle M. Estrella

  • Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

    Anton Pozniak;Jose R. Arribas;Joseph Gathe;Samir K. Gupta

  • Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.

    Tanya Welz;Kate Childs;Fowzia Ibrahim;Mary Poulton

  • British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011

    D Asboe;C Aitken;M Boffito;C Booth

  • Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK.

    Chloe I Bloom;Thomas M Drake;Annemarie B Docherty;Brian J Lipworth

  • Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

    Samir K. Gupta;Frank A. Post;José R. Arribas;Joseph J. Eron

  • Pulmonary tuberculosis in HIV infection: Radiographic appearance is related to CD4+ T-lymphocyte count

    Frank Post;R Wood;G P Pillay

  • Spectrum of chronic kidney disease in HIV‐infected patients

    Lj J. Campbell;F. Ibrahim;M. Fisher;Sg G. Holt

  • Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

    Nicholas I. Paton;Ruth L. Goodall;David T. Dunn;Samuel Franzen

  • CD4 and total lymphocyte counts as predictors of HIV disease progression.

    Frank Post;R Wood;G Maartens

  • HIV care and the incidence of acute renal failure.

    Jennifer Roe;Lucy J. Campbell;Fowzia Ibrahim;Bruce M. Hendry

  • Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

    S Fidler;W Stöhr;M Pace;L Dorrell

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

    Duncan Churchill;Laura Waters;Nadia Ahmed;Brian Angus

Frequent Co-Authors

Caroline Sabin
Caroline Sabin University College London
Alan Winston
Alan Winston Imperial College London
Clifford Leen
Clifford Leen Western General Hospital
Martin Fisher
Martin Fisher University of Sussex
Marta Boffito
Marta Boffito Imperial College London
Chloe Orkin
Chloe Orkin Queen Mary University of London
Richard Gilson
Richard Gilson University College London
Margaret Johnson
Margaret Johnson The Royal Free Hospital
Andrew N. Phillips
Andrew N. Phillips University College London
Robert F. Miller
Robert F. Miller University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, exploring related online degrees can expand their career opportunities in healthcare and research. Many nursing professionals consider advancing their education through programs like the easiest fnp program, designed for Family Nurse Practitioners seeking flexible learning options without compromising quality.

Those focused on mental health aspects may find value in online pmhnp programs with clinical placement. These programs emphasize practical experience and often feature robust partnerships with healthcare facilities, ensuring graduates are well-prepared for hands-on work.

Cost is another crucial factor for many students. Exploring the cheapest psych np programs can help aspiring Psychiatric Nurse Practitioners achieve their goals with minimal financial burden.

Finally, understanding compensation trends is essential for making informed career decisions. Resources like the dnp salary transparency guide provide valuable insights into salary variations across states for Doctor of Nursing Practice graduates, helping students target their job search effectively.

Best Scientists Citing Frank A. Post

Trending Scientists

Recently Published Articles